3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
64
Head and Neck Neoplasms
63
Squamous Cell Carcinoma of Head and Neck
60
Carcinoma, Non-Small-Cell Lung
34
Rectal Neoplasms
23
Colonic Neoplasms
23
Neoplasm Metastasis
19
Neoplasms
18
Carcinoma, Squamous Cell
17
Pancreatic Neoplasms
13
Lung Neoplasms
13
Esophageal Neoplasms
11
Tongue Neoplasms
9
Stomach Neoplasms
9
Recurrence
9
Carcinoma
8
Neoplasms, Squamous Cell
6
Mouth Neoplasms
6
Laryngeal Neoplasms
6
Breast Neoplasms
6
Adenocarcinoma Of Esophagus
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Esophageal Squamous Cell Carcinoma
5
Adenocarcinoma of Lung
5
Sarcoma
4
Salivary Gland Neoplasms
4
Oropharyngeal Neoplasms
4
Laryngeal Diseases
4
Precancerous Conditions
3
Hypopharyngeal Neoplasms
3
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metatropic dwarfism
×
Cetuximab
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts